{"id":2640,"date":"2017-08-30T10:52:50","date_gmt":"2017-08-30T10:52:50","guid":{"rendered":"http:\/\/www.medicalmarijuanainc.com\/?p=26001"},"modified":"2017-08-30T10:52:50","modified_gmt":"2017-08-30T10:52:50","slug":"cbd-oil-center-discussion-upcoming-international-epilepsy-congress","status":"publish","type":"post","link":"https:\/\/medicalmarijuanainc.com\/2017\/08\/30\/cbd-oil-center-discussion-upcoming-international-epilepsy-congress\/","title":{"rendered":"CBD Oil to be Center of Discussion at Upcoming International Epilepsy Congress"},"content":{"rendered":"
[vc_row][vc_column][vc_column_text]HempMeds\u00ae Mexico and its flagship product, Real Scientific Hemp Oil-X\u2122 (RSHO-X\u2122), will be an important part of the conversation surrounding the treatment of seizures at next week\u2019s 32nd International Epilepsy Congress in Barcelona, Spain. <\/span><\/p>\n Scheduled for September 2-6, the <\/span>International Epilepsy Congress<\/span><\/a> gives attendees the unique opportunity to interact face to face with some of the field\u2019s important researchers and reveal latest developments in our understanding of epilepsy. RSHO-X\u2122\u2019s efficacy in the treatment of epilepsy will be presented at the event by noted pediatric neurologist, Dr. Saul Garza.<\/span><\/p>\n At the International Epilepsy Congress, Dr. Garza will outline his <\/span>recent study<\/span><\/a> using RSHO-X as a method of treatment for Lennox-Gastaut Syndrome (LGS). The study included 39 patients with Lennox-Gastaut syndrome, a severe form of pediatric epilepsy. In those 39 patients, an 84% average reduction in motor seizures were experienced; 53% of patients reported better than a 75% reduction in seizures; and 17% reported a complete elimination of all seizures over a 4-month period. No adverse side effects were reported among the patient population. Dr. Garza\u2019s presentation will be at 1:30 p.m. on Sunday, September 3.<\/span>[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_single_image image=”17975″ img_size=”1200×250″ onclick=”custom_link” link=”https:\/\/www.medicalmarijuanainc.com\/what-is-cbd-oil\/”][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text]\u201cWe are thrilled that Dr. Garza was chosen to present his findings at the International Epilepsy Congress as this study shows our botanical CBD to provide the best available therapeutic intervention within this epilepsy patient population.\u00a0 Given the advanced nature of these children’s conditions, it is pretty remarkable that 17% of the Lennox-Gastaut Syndrome patients experienced a total, 100% relief from their seizure episodes” said CEO of Medical Marijuana, Inc. Dr. Stuart Titus. \u201cStudies like Dr. Garza\u2019s help prove that the therapeutic benefits of botanically-oriented CBD are real and are helping fuel increased access to medical cannabis programs across the globe.\u201d<\/p>\n First developed for the Mexican market, THC-free RSHO-X\u2122 has played an important role in the progress of <\/span>medical cannabis legalization<\/span><\/a> in the country. RSHO-X\u2122 was initially imported into Mexico for Graciela Elizalde Benavides. Diagnosed with Lennox-Gastaut syndrome, Grace was suffering up to 400 seizures daily. After her family took the Mexican government to court, RSHO-X\u2122 was authorized as a treatment for Grace. This opened the door for more and more patients with a variety of medical conditions to access CBD oil and created a shift in the perception of medical cannabis in Mexico. <\/span>[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_single_image image=”17963″ img_size=”1200×250″ onclick=”custom_link” link=”https:\/\/hempmeds.mx\/”][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text]<\/p>\n Across the European Union, CBD oil products derived from hemp can be sold as dietary supplements. In the EU, hemp must contain no more than 0.2% THC per dry weight. If products meet EU criteria, then they can be sold throughout the European Union. <\/span><\/p>\n In Spain, this legality was verified in 2009 when the Court of Justice handed down a categorical ruling on <\/span>Case C\u201188\/07 (Commission of the European Communities v Kingdom of Spain) <\/span><\/a>on the free movement of goods and products classified as medicinal products and products lawfully produced or marketed as food supplements or dietary products in other EU member states.<\/span><\/p>\n Like in other markets in the EU and around the world, there is a growing desire for CBD oil products that is driving a cultural shift in the perception of cannabinoids and their therapeutic potential.<\/p>\nEfficacy of CBD Oil<\/span><\/h2>\n
RSHO-X\u2122 in Mexico<\/span><\/h2>\n
CBD Oil in Spain and the European Union<\/span><\/h2>\n